{Reference Type}: Journal Article
{Title}: Abemaciclib for treating patients with HR+/HER2- metastatic breast cancer: a real-world study in France, Italy and Spain.
{Author}: Blancas I;Grosjean J;Pedersini R;Buzzoni C;Sleilaty G;Molero A;Tamma A;Chouaki N;Atienza M;Emde A;Siddi S;Bayona RS;Mastro LD;Fakhouri W;
{Journal}: Future Oncol
{Volume}: 0
{Issue}: 0
{Year}: 2024 Aug 8
{Factor}: 3.674
{DOI}: 10.1080/14796694.2024.2368455
{Abstract}: Aim: This real-world study aimed to describe patient and clinical characteristics, treatment patterns and outcomes for patients with HR+/HER2- metastatic breast cancer receiving abemaciclib in France, Italy and Spain. Materials & methods: A multicenter chart review was conducted for adult females with HR+/HER2- advanced/metastatic breast cancer who received abemaciclib in routine care. Real-world progression-free survival (rwPFS) was estimated via Kaplan-Meier curves. Results: This study included 151, 173 and 175 patients from France, Italy and Spain, respectively. Abemaciclib was mostly prescribed as first-line therapy concomitantly with hormone therapy. Median rwPFS was >20 months and the 1-year rwPFS rate was >70%. Conclusion: Effectiveness was similar across the three countries and aligns with pivotal studies.<BR>Abemaciclib use in the clinic in France, Italy & SpainThis study describes patients, the treatments they have received and the results of those treatments for patients with the most common type of advanced breast cancer. These patients were taking abemaciclib plus hormonal therapy in routine breast cancer care in France, Italy and Spain. The information used to conduct this study was taken from patients' medical charts. In this real-world study, abemaciclib was mostly used as the initial treatment for advanced breast cancer. Abemaciclib effectiveness was similar across the three countries confirming findings from previous studies. Our study supports the use of abemaciclib for patients with HR+/HER2- advanced breast cancer.